OmniAb (OABI) Q3 2026 Earnings Call Transcript
OmniAb (OABI) reported Q3 2026 earnings, highlighting a new partnership with Lilly, which includes an upfront payment and up to $370M in potential milestone payments. The company saw increased utilization of its technologies and strong traction with its xPloration platform. OmniAb also launched OmniTides, a new peptide discovery offering. The company raised its 2026 revenue and cash outlook, and reported 111 active partners and 433 active programs as of Q3.
How this was made
The 30-second read
Why it matters
The disclosed milestones and guidance raise suggest a material re‑rating opportunity for the stock.
Market read
First report of sizable milestone potential and updated guidance makes this a high‑impact earnings update.
What to watch
Potential dilution from future equity raises to fund expanded programs could offset some upside.
Background
OmniAb's Q3 2026 earnings call covered partnership growth, new licensing deals, program metrics, and a recent Chinese approval for batoclimab.
Ticker impact
OmniAb disclosed a new license deal with Lilly including an upfront payment and up to $370M in milestones, plus updated guidance and program metrics.
likely upside as the market incorporates the new milestone upside and guidance raise
First disclosure of a sizable $370M milestone opportunity and $3B total contracted potential, plus guidance lift, provides fresh material for valuation.
Market effects
Strengthens the biotech licensing sector as OmniAb's platform gains more pharma partners.
Positive for US biotech investors; China approval of batoclimab may boost Asian biotech sentiment.
Highlights growing importance of AI‑driven discovery platforms worldwide.
Counterpoint
If milestone payments are delayed or contingent, the upside may be overstated.
Key entities
- partnerEli Lilly
Entered a new licensing agreement with OmniAb.
- productBatoclimab
Received Chinese regulatory approval, marking the fourth platform drug approval.
